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a b s t r a c t
Introduction: The aim of this study was to determine risk factors for acquiring carbapenem-
resistant Pseudomonas aeruginosa bacteremia (CR-PA) and factors associated with in-hospital
mortality.
Methods: Seventy-seven cases of bacteremia caused by P. aeruginosa were evaluated in a
hospital with high incidence of CR-PA. Clinical and laboratorial factors, and previous use
of antibiotics were also evaluated. In one analysis, CR-PA and carbapenem-susceptible P.
aeruginosa (CS-PA) bacteremia were compared. A second analysis compared patients who
died with survivors.
Results: Among 77 P. aeruginosa bacteremia, 29 were caused by CR-PA. Admission to the
intensive care unit, higher number of total leukocytes, and previous use of carbapenem
were statistically associated with CR-PA. In the multivariate analysis, only previous use of
carbapenem (including ertapenem) turned out to be a risk factor for CR-PA (p=0.014). The 30-
day mortality of patients with P. aeruginosa bloodstream infection was 44.8% for CS-PA and
54.2% for patients with CR-PA (p=0.288). Chronic renal failure, admission to the intensive
careunit,mechanical ventilation, and central venous catheterwere risk factors formortality.
Incorrect treatment increased mortality of patients with bacteremia caused by CS-PA, but
not for CR-SA. The odd ratio of mortality associated with incorrect therapy in patients with
CS-PA was 3.30 (1.01–10.82; p= 0.043). The mortality of patients with bacteremia caused byCR-PA was unexpectedly similar regardless of antimicrobial treatment adequacy.
Conclusion: Appropriate treatment for CS-PA bacteremia initiated within the ﬁrst 24hours
was associated with lower mortality, but this cannot be extrapolated for CR-PA.
infections. In some hospitals, P. aeruginosa can be the ﬁrst
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those who survived. Continuous data were expressed as
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Fig. 1 – Survival curve of patients with Pseudomonas352 braz j infect d
to developing countries, where environmental conditions
favor Gram-negative bacilli infections.5 Some risk factors for
Pseudomonas bacteremia have been described as increased
age, hemodialysis, solid organ transplant, neoplasms, heart
disease, diabetes mellitus, and chronic obstructive airway
disease.6 However, these factors are unalterable, and efforts
should focus on appropriate antibiotic therapy and preven-
tion.
Resistance of P. aeruginosa against antipseudomonal drugs
has increased due to different trends in several regions of
the world. The choice of an ideal empiric antibiotic against
a possible infection caused by P. aeruginosa has been a chal-
lenge. The mechanisms of resistance are complex, involving
acquisition genes (mainly against beta-lactams and amino-
glycosides) and chromosomal genes (against ﬂuorquinolones).
Carbapenem has been one of the most important classes of
antibiotics used in the empirical treatment of nosocomial
infections, mainly in severe cases. However, resistance of P.
aeruginosa to imipenem and meropenem has reached more
than 70% in somehospitals in Brazil.7,8 Themainmechanisms
of resistance to carbapenem are the loss of the OprDm efﬂux
bomb and production of metallo-beta-lactamases, the latter
may correspond up to 30% in a previous study in the South of
Brazil.9–11
The multidrug-resistant P. aeruginosa is associated with
increased mortality and costs due to prolonged hospital-
ization, need of surgery, and prolonged treatment with
antibiotics.12 Considering the endemic condition of Pseu-
domonas infection in hospitals, the question is whether there
is a certain risk group for multi-drug resistant (MDR) Pseu-
domonas infection, or are all the patients under such risk.
Considering the current scenario, a case-control study
was performed to determine the risk factors associated with
bacteremia caused by carbapenem-resistant P. aeruginosa (CR-
PA), using as a control patients with carbapenem-susceptible
strains of P. aeruginosa (CS-PA). Factors associated with mor-
tality and other outcomes, especially the choice of antibiotic
treatment for CR-PA, were also evaluated.
Patients and methods
Patients
A case control study was carried out at the Hospital Uni-
versitário Evangélico de Curitiba. This center is a 660-bed
tertiary-care hospital in Curitiba, a city located in Southern
Brazil. It is a reference center for trauma, burns, and renal
transplantation with 60 intensive care beds.
All the patients older than 18 years with bacteremia
caused by P. aeruginosa from February, 2006 to January, 2009
were included. Patients with more than one episode of
Pseudomonas bacteremia were included once. Patients with
bacteremia caused by other microorganism before P. aerugi-
nosa were excluded.Microbiological deﬁnition
Cultures were collected according to the standard proto-
col used in the hospital and were processed using the12;16(4):351–356
BACT/Alert® (bioMérieux–Durham, USA). P. aeruginosa was
identiﬁed using biochemical analysis.13 Susceptibility test-
ing was performed by the disk diffusion method according
to the Clinical and Laboratory Standards Institute (CLSI)
guidelines.14
Clinical ﬁndings
The following variables were evaluated for each patient: gen-
der; age; previous hospital admission within the last 90 days;
admission to the intensive care unit (ICU); length of hospi-
talization before bacteremia; use of mechanical ventilation,
central venous line, urinary catheter and surgery during the
current hospitalization; underlying conditions such as dia-
betes mellitus, chronic renal failure, heart failure, and cancer;
trauma and previous antibiotic use during current hospital-
ization; previous colonization by P. aeruginosa. The following
laboratory parameters were evaluated on the day of diagnosis:
hemoglobin, leukocyte, platelet counts, and creatinine.
Thirty-day and in-hospital mortality were registered.
Antibiotic treatment was classiﬁed as correct or incorrect.
Treatment of each patient was considered correct if the P.
aeruginosa strainwas susceptible to the antibiotic used/started
in less than 24hours after blood collection.
Analysis of data
Patients with CR-PA bacteremia were compared with patients
with CS-PA bacteremia to determine factors associated with
carbapenem resistance. A second analysis was performed
comparing patients who died during hospitalization withaeruginosa bacteremia under correct or incorrect therapy
considering the susceptibility pattern of the microorganism
to carbapenem. CR-PA, carbapenem-resistant P. aeruginosa;
CS-PA, carbapenem-susceptible P. aeruginosa.
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Table 1 – Risk factors for carbapenem-resistant Pseudomonas aeruginosa bacteremia. Risk factors were compared with
susceptible strains. Values are pictured as absolute numbers followed by percentage.
Characteristic Carbapenem-resistant Carbapenem-susceptible OR (95%CI) p
(n=29) (n=48)
Age–years
Mean 46.4± 22.71 49.0± 20.4 0.601
Gender–n (%)
Male 22 (75.9) 34 (70.8) 1.30 (0.45–3.85) 0.418
Female 7 (24.1) 14 (29.2)
Coexisting diseases–n (%)
Comorbities 12 (41.4) 29 (60.4) 0.46 (0.18–1.19) 0.083
Diabetes mellitus 4 (13.8) 7 (14.6) 0.94 (0.24–3.57) 0.602
Chronic renal failure 4 (13.8) 6 (12.5) 1.12 (0.29–3.57) 0.565
Heart failure 0 (0.0) 2 (4.2) * 0.386
Hypertension 6 (20.7) 13 (27.1) 0.70 (0.23–2.13) 0.364
COPD 1 (3.4) 1 (2.1) 1.69 (0.10–33.33) 0.614
Cancer 2 (6.9) 9 (18.8) 0.32 (0.06–1.61) 0.134
Trauma 12 (41.4) 11 (22.9) 2.38 (0.88–6.67) 0.073
Burn 3 (10.3) 9 (18.8) 0.50 (0.12–2.04) 0.259
Hospitalization before Pseudomonas–days 24.6± 20.9 19.6± 18.6 0.66
Total duration of hospitalization–days 43.0± 31.7 43.1± 31.2 0.987
Other factors–n (%)
Intensive care unit 24 (82.8) 25 (52.1) 4.55 (1.45–14.29) 0.006
Previous hospitalization 7 (24.1) 16 (33.3) 0.64 (0.22–1.82) 0.277
Previous Pseudomonas colonization 14 (48.3) 14 (29.2) 2.27 (0.97–6.25) 0.075
Mechanical ventilation 23 (79.3) 29 (60.4) 2.56 (0.87–7.69) 0.070
Central venous catheter 25 (86.2) 37 (77.1) 1.89 (0.53–6.67) 0.251
Urinary catheter 26 (89.7) 39 (81.3) 2.00 (0.50–8.33) 0.259
Surgery 4 (13.8) 8 (16.7) 0.80 (0.22–2.94) 0.503
Laboratory values–mean± SD
Hemoglobin (g/dL) 10.3± 2.0 10.0± 2.2 0.608
Leucocytes (1000× cells/mm3) 15.8± 9.0 11.9± 6.9 0.035
Immature cells (%) 17.2± 14.1 17.8± 14.0 0.853
Platelets (1000× cells/mm3) 184.4± 152.1 169.7± 173.3 0.778
Creatinine (mg/dL) 1.5± 1.7 1.8± 2.3 0.459
Previous antibiotic use 22 (75.9) 29 (60.4) 2.08 (0.74–5.88) 0.127
3rd and 4th generation cephalosporin 13 (44.8) 15 (31.3) 1.82 (0.69–4.76) 0.170
3rd generation cephalosporin 5 (17.2) 9 (18.8) 0.91 (0.27–3.03) 0.561
4th generation cephalosporin 10 (34.5) 8 (16.7) 2.63 (0.90–8.33) 0.067
Piperacillin/tazobactam 4 (13.8) 6 (12.5) 1.12 (0.29–4.55) 0.565
Quinolone 1 (3.4) 2 (4.2) 0.83 (0.07–10.00) 0.684
Carbapenem 20 (69.0) 17 (35.4) 4.17 (1.52–11.11) 0.004
Ertapenem 9 (31.0) 10 (20.8) 1.72 (0.60–5.00) 0.230
Imipenem or meropenem 15 (51.7) 14 (29.2) 2.63 (1.00–7.14) 0.042












cOR, odds ratio; COPD, chronic obstructive pulmonary disease.
ompared with the non-parametric test Kruskal-Wallis.
ichotomous variables were compared using the chi-square
2) test, and the Mann Whitney test was used for continuous
ariables. Signiﬁcance level was set at 0.05. Variables in which
<0.10 in the univariate analysis were included in the multi-
ariate analysis. Multivariate analysis was performed using a
orward factorial binary logistic regression model. Odds ratios
OR) with 95% conﬁdence intervals (95% CI) were calculated
or each variable. Variables in which 95% CI did not include 1.0
ere maintained in the ﬁnal model.
Kaplan-Meier survival estimates were calculated to evalu-
te the role of correct treatment in the outcome of bacteremia
aused by CR-PA, and the difference was assessed using thelog-rank test. Signiﬁcance was determined when the p-value
was lower than 0.05.
All data were recorded using the software Excel
(Microsoft–New York, USA) and analyzed with the free
software R, version 2.11 (The R Foundation for Statistical Com-
puting). Kaplan-Meier survival estimates were determined
with GraphPad Prism 4.0 (GraphPad–La Jolla, USA).Results
A total of 77 patients were included in this study. Twenty-
nine patients presented CR-PA bacteremia and 48 patients had
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Table 2 – Risk factors for mortality of patients with Pseudomonas aeruginosa bacteremia. Values are given as absolute
number followed by percentage.
Characteristic Survival Death OR (95%CI) p
(n=39) (n=38)
Age–years
Mean 45.3± 21.8 50.6± 20.5 0.281
Gender–n (%)
Male 26 (68.4) 30 (76.9) 0.65 (0.23–1.78) 0.281
Female 12 (31.6) 9 (23.1)
Coexisting diseases–n (%)
Comorbities 20 (52.6) 21 (53.8) 0.95 (0.38–2.33) 0.548
Diabetes mellitus 33 (86.8) 33 (84.6) 0.83 (0.23–3.00) 0.519
Chronic renal failure 8 (21.1) 2 (5.1) 4.93 (0.974–24.99) 0.039
Heart failure 1 (2.6) 1 (2.6) 1.2 (0.06–17.03) 0.747
Hypertension 7 (18.4) 12 (30.8) 0.50 (0.17–1.47) 0.161
COPD 0 (0.0) 2 (5.1) – 0.253
Cancer 7 (18.4) 4 (10.3) 1.97 (0.52–7.39) 0.243
Trauma 11 (28.9) 12 (30.8) 0.91 (0.34–2.43) 0.530
Burn 5 (13.2) 7 (17.9) 0.69 (0.19–2.40) 0.396
Hospitalization before Pseudomonas–days 18.3± 21.5 24.6± 19.2 0.066
Total duration of hospitalization–days 38.2± 26.4 48.0± 35.2 0.173
Other factors–n (%)
Intensive care unit 18 (47.4) 31 (79.5) 0.23 (0.08–0.63) 0.003
Previous hospitalization 13 (34.2) 10 (25.6) 1.50 (0.56–4.02) 0.284
Previous Pseudomonas colonization 11 (28.9) 17 (43.6) 0.52 (0.20–1.35) 0.136
Mechanical ventilation 18 (47.4) 34 (87.2) 0.13 (0.04–0.41) <0.001
Central venous catheter 26 (68.4) 36 (92.3) 0.18 (0.04–0.70) 0.008
Urinary catheter 29 (76.3) 36 (92.3) 0.26 (0.06–1.08) 0.051
Surgery 6 (15.8) 6 (15.4) 1.03 (0.30–3.53) 0.604
Laboratorial ﬁndings–mean± SD
Hemoglobin (g/dL) 10.1± 2.1 10.1± 2.6 0.951
Leucocytes (1000x cells/mm3) 13.0± 0.6 13.7± 0.6 0.988
Immature cells (%) 13.1± 13.2 21.9± 13.4 0.001
Platelets (1000x cells/mm3) 221.4± 183.3 133.0± 130.0 0.137
Creatinine (mg/dL) 2.1± 2.7 1.3± 1.2 0.444
Previous antibiotic use 23 (60.5) 28 (71.8) 0.60 (0.23–1.53) 0.211
3rd and 4th generation cephalosporin 10 (26.3) 18 (46.2) 0.41 (0.16–1.08) 0.058
3rd generation cephalosporin 5 (13.2) 9 (23.1) 0.50 (0.15–1.67) 0.203
4th generation cephalosporin 8 (21.1) 10 (25.6) 0.77 (0.28–2.23) 0.419
Piperacillin/tazobactam 6 (15.8) 4 (10.3) 1.64 (0.42–6.34) 0.351
Quinolone 3 (7.9) 0 (0.0) – 0.115
Carbapenem 14 (36.8) 23 (59.0) 0.40 (0.16–1.01) 0.043
Ertapenem 5 (13.2) 14 (35.9) 0.27 (0.08–0.85) 0.019
Imipenem or meropenem 12 (31.6) 17 (43.6) 0.59 (0.23–1.51) 0.197
OR, odds ratio; COPD, chronic obstructive pulmonary disease.
Table 3 – Mortality of patients with Pseudomonas aeruginosa bacteremia comparing the correct therapy between
carbapenem-resistant strains with those susceptible.
Characteristic Death Survival OR (95%CI) p
(n=39) (n=38)
Carbapenem-susceptible
Correct 9 (39) 14 (61) 3.30 (1.01–10.82) 0.043
Incorrect 17 (68) 8 (32)
Carbapenem-resistant
Correct 4 (50) 4 (50) 0.75 (0.14–3.84) 0.526
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S-PA bacteremia. The median age was 49 years-old in the
R-PA group, and 46.5 in the CS-PA group, with no signiﬁcant
ifference, using parametric (for mean) or non-parametric (for
edian) tests.
The duration of hospitalization before bacteremia was not
ifferent between the groups, although it had a tendency to
e prolonged in the CR-PA group, with a median of 13.5 days
n the CS-PA group and 20.0 days in the CR-PA group. The time
f hospitalization was also not different between groups.
All the clinical and laboratorial data are detailed in the
able 1. Even though several variables were compared, admis-
ion at the intensive care unit, higher number of total
eukocytes, and previous use of carbapenem were statistically
igniﬁcant. In the multivariate analysis only previous use of
arbapenem (including ertapenem) remained as an indepen-
ent risk factor for CR-PA (p=0.014).
The 30-day mortality of patients with P. aeruginosa blood-
tream infection was 44.8% for patients with CS-PA and 54.2%
or patients with CR-PA, without statistical signiﬁcance. The
nivariate analyses of factors associatedwith in-hospitalmor-
ality are listed in Table 2. Chronic renal failure, admission to
he ICU, mechanical ventilation, and central venous catheter
ere risk factors for mortality. The percentage of immature
hite cells was higher in patients who died. The multivariate
nalysis did not single out any isolated risk factor formortality
f patients with P. aeruginosa.
The treatment of bacteremia was incorrect in 46 of
7 patients (59.7%). Incorrect treatment increased mortality
hen compared to correct treatment of patients with bac-
eremia caused by CS-PA (39% vs. 68%; p=0.043), but not by
R-SA (43% vs. 50%; p=0.526) [OR: 3.30 (95% CI: 1.01–10.82;
= 0.043] (Table 3). The mortality of patients with bacteremia
aused by CR-PA was similar irrespective of correct or incor-
ect antimicrobial treatment. Fig. 1 shows the different pattern
f survival curves among the four groups (correct and incor-
ect therapy for CS-PA and CR-PA). There was no difference
mong the groups, although there was a tendency of higher
ortality in groups with incorrect therapy, including a higher
iscrepancy in the group of CS-PA, as detailed in Table 3.
iscussion
arbapenem has failed in the last years as a drug of choice
n the treatment of nosocomial sepsis, considering the cur-
ent resistance scenario. This group has published a recent
tudy about the importance of including polymyxin as one
f the drugs of choice in the empirical treatment of infec-
ions in hospitalized patients.15 Furthermore, the duration of
ospitalization before bacteremia was not different between
arbapenem-susceptible and carbapenen-resistant strains.
owever, the mean hospital length of stay before the ﬁrst
seudomonas bacteremia with CR-PA had a tendency to be
reater. This ﬁnding was also reported in bacteremia caused
y ESBL producing Enterobacteriaceae in the same hospital,16
uggesting that bacteremia by MDR bacteria occurs later.
nfortunately, the wide range of hospital length of stay before
he ﬁrst bacteremia does not allow for the determination
f an ideal therapy considering only the day of hospitaliza-
ion.2;16(4):351–356 355
PatientswithCR-PAweremainly in the ICU, undermechan-
ical ventilation and with invasive procedures (e.g. central
venous catheter). In a previous study invoving over 503
patients, independent risk factors for pan-resistant Pseu-
domonas bloodstream infection included previous transplan-
tation, hospital-acquired infection, and prior ICU admission
(OR 2.04; 95% CI: 1.15–3.63, p= 0.015).17 The most interesting
ﬁnding in the present study was the association with previous
use of carbapenem, although this had already been described
in the literature.18,19
The mortality of Pseudomonas bacteremia has been evalu-
ated in large series of retrospective studies, including regional
studies from Brazil. There was a tendency of higher mortality
in the group of CR-PA in the literature, but not in all studies.
Some of them do not attribute the mortality to the agent, but
to the underline condition of the patientwhodeveloped aMDR
Pseudomonas bacteremia.20 Another well-detailed characteris-
tic of CR-PA is incorrect therapy. Zavascki et al. showed that
metallo-beta-lactamase-producing P. aeruginosa increases the
risk of incorrect therapy, increasing the mortality.21
The delay to begin the correct antibiotic therapy is associ-
ated with higher mortality in several studies among different
species.22 This study demonstrated that this concept is not
a constant, and is mainly associated with older patients and
those with severe diseases as well as those infected with MDR
bacteria.16,23 In the survival curve of the present study, there
was a non-signiﬁcant trend for higher mortality among those
with incorrect therapy, probably due to small sample size in
the subgroup analysis. All patients deﬁned as receiving correct
therapy started the drug in less than 24h after blood sam-
ple collection. The treatment options for CR-PA are scarce.
Polymyxin B was the main drug used in this context, given
that the samples in this hospital are pan-resistant. The dose
of polymyxin B used in this institution is 25,000 IU/kg q12h,
without dose adjust in the presence of renal failure.
This study conﬁrmed these ﬁndings only for the CS-PA
group. Probably, the CR-PA group did not show the decreased
mortality due to severity of infection in the group with previ-
ous use of carbapenems, as demonstrated in the Table 1. It is
suggested that there is a group of patients in which antibiotic
therapy does not impact mortality.24,25
In conclusion, Pseudomonas bacteremia presents a high
mortality, which can be reduced when correct therapy is
employed, at least when carbapenem-susceptible strains are
identiﬁed. Correct therapy does not necessarily change the
evolution of CR-PA.
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